Company intelligence / Profile preview
Diapin Therapeutics
- Ownership
- Private
- Employees
- ~6
- Development stage
- Preclinical
Overview
Diapin Therapeutics is developing DT678, a novel prodrug that directly forms the active metabolite of clopidogrel without hepatic activation, potentially ensuring consistent efficacy across all patient populations including those with CYP2C19 mutations. The company has received FDA feedback for potential expedited development of DT678 as a promising antiplatelet therapy. Their second program, DT109, is a tripeptide targeting multiple indications including MASH, Primary Biliary Cholangitis, and Type 2 Diabetes.[5]
- Therapeutic areas
- Metabolic DisordersEndocrinologyGastroenterologyCardiovascularNeurology
- Modalities
- Small molecule drugsRecombinant polypeptidesPeptides
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Diapin Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Diapin Therapeutics.